Advanced in Teratoma of the Mediastinum

Michelle Lockley

Charterhouse Square, 
London, ENG, GB 
Advanced in Teratoma of the Mediastinum
Charterhouse Square, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Michelle Lockley practices in London, United Kingdom. Ms. Lockley is rated as an Advanced expert by MediFind in the treatment of Teratoma of the Mediastinum. Her top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Teratoma of the Mediastinum, Oophorectomy, and Salpingo-Oophorectomy.

Her clinical research consists of co-authoring 63 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Teratoma of the Mediastinum.

Gender
Female

Locations

Charterhouse Square, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Terminated
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer
Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

63 Total Publications

Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control.
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control.
Journal: Cancer research
Published: January 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lockley's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile